Molluscum Contagiosum Mc Market

DelveInsight’s ‘Molluscum Contagiosum Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of Molluscum Contagiosum, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

Molluscum Contagiosum market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted Molluscum Contagiosum market size from 2019 to 2032 segmented by seven major markets. The report also covers current Molluscum Contagiosum symptoms, treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

 

Molluscum Contagiosum Market

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Molluscum Contagiosum Disease Understanding and Treatment Algorithm

Molluscum Contagiosum Overview

Molluscum Contagiosum, also called water warts, is a common superficial skin infection caused by the poxvirus. Molluscum Contagiosum Virus (MCV) is one of the 50 most frequent diseases worldwide. It predominantly affects school-aged children, sexually active young adults, and immune compromised individuals. It is characterized by painless white or skin-colored papular skin lesions that are generally 2–5 mm in size, though early lesions can be smaller. The skin lesions of MC are called mollusca, and a patient typically has 1-20 mollusca. In normal hosts, MC is benign natured and limited to the skin, but lesions can take as long as 6–12 months to resolve. Immuno compromised patients can develop very large (>15 mm) and numerous lesions and bacterial super infections.

 

Molluscum Contagiosum Diagnosis and Treatment

DelveInsight’s Molluscum Contagiosum report covers the details of conventional and current medical therapies and diagnoses available in the Molluscum Contagiosum market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The major therapeutic modalities employed are physical destruction, immunomodulation, and antiviral agents, and combinations of these therapies may be employed. The physical destruction of lesions may be done by cryotherapy, curettage, laser, salicylic acid, and other methods; however, these procedures can be painful and engender scarring. Alternatively, immune-modulating therapies, such as topical imiquimod or cimetidine, have been used to speed the healing of MC lesions; however, there is limited information to show these are effective, and imiquimod has known side effects.

 

A few major unmet needs in the market include the absence of commonly accepted standard of care, no consensus on clinical practice treatment guidelines, lack of refined and advanced clinical trial design, limited availability of epidemiological studies, among others.

Molluscum Contagiosum Epidemiology

The Molluscum Contagiosum symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The total prevalent cases of Molluscum Contagiosum patients in the 7MM are increasing during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Molluscum Contagiosum symptoms epidemiology segmented as the total prevalent cases and gender-specific cases of Molluscum Contagiosum. The report includes the prevalent cases scenario of Molluscum Contagiosum in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Molluscum Contagiosum Epidemiology

The epidemiology segment also provides the Molluscum Contagiosum epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total number of prevalent cases of Molluscum Contagiosum associated in 7MM countries was around 12.5 million in 2021.

Molluscum Contagiosum drug Chapters

Molluscum Contagiosum drug chapter segment encloses the detailed analysis of Molluscum Contagiosum early-stage (Phase I, II, and III) pipeline drugs. It also helps to understand the Molluscum Contagiosum clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Molluscum Contagiosum Emerging Drugs

 

VP-102/Cantharidin: Verrica Pharmaceuticals

VP-102 is a proprietary drug-device combination developed by Verrica Pharmaceuticals as topical therapy, containing (0.7% w/v) of cantharidin solution designed to treat MC, common warts, and external genital warts. The patented drug-device combination is available in the single-use precision applicator for ease of administration. It is a GMP-controlled formulation of cantharidin with more than 99% pure API and a pharmaceutical batch process defined with respect to safety, purity, and stability. The active ingredient, cantharidin, is a naturally occurring vesicant that causes the degradation of desmosomal plaques, which helps treat topical dermatological conditions. Cantharidin is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A) that have keratolytic features inducing acantholysis.

 

VP-102 has the potential to be a first-in-class treatment. Verrica Pharmaceuticals submitted an NDA for VP-102 to the US FDA for the treatment of treat MC, following positive results from two pivotal Phase III trials. Verrica Pharmaceuticals is planning to meet with the FDA to determine the next steps in the development of VP-102 for common warts after successfully completing Phase II with positive results.

Other Products detailed in the report…

 

Molluscum Contagiosum Market Outlook

The market outlook helps to better understand the historic, current and forecasted Molluscum Contagiosum market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of Molluscum Contagiosum market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

 

According to DelveInsight, the Molluscum Contagiosum market in 7MM is expected to grow steadily during the study period 2019–2032.

 

As Molluscum Contagiosum is a self-limited in healthy individuals, treatment may not be essential. Nonetheless, issues such as lesion visibility, underlying atopic disease, and the desire to prevent transmission may prompt therapy. Molluscum has a myriad of clinical presentations based on the anatomic location affected and has the potential to become a debilitating infection. Treatment for molluscum is usually recommended if lesions are in the genital area (on or near the penis, vulva, vagina, or anus). There is a consensus that treatment should be indicated in patients with extensive disease, secondary complications (bacterial super infection, molluscum dermatitis, conjunctivitis), or aesthetic complaints.

 

Treatment, until recently, has been limited to tissue destruction, including curettage, cryotherapy, CO2 laser, electrodessication, trichloracetic acid, and cantharadin. Recently, topical immune modulators have been used with some success. However, these treatments do not eradicate MCV but merely hold it at bay.

Key Findings

This section includes a glimpse of the Molluscum Contagiosum market in 7MM. Molluscum Contagiosum market size in the seven major markets was around USD 2 billion in 2021.

 

The United States Market Outlook

This section provides the total Molluscum Contagiosum market size and market size by therapies in the United States.

 

The United States accounts for the largest market size of Molluscum Contagiosum compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Molluscum Contagiosum market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Molluscum Contagiosum market size and market size by therapies in Japan are also mentioned.

Molluscum Contagiosum Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers the Molluscum Contagiosum market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps to understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Molluscum Contagiosum Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Molluscum Contagiosum key players involved in developing targeted therapeutics.

 

Major market players include Verrica Pharma, Novan / Ligand Pharma, Veloce Biopharma, among others.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Molluscum Contagiosum emerging therapies.

 

In May 2019, Ligand Pharmaceuticals entered into a development funding and royalties agreement with Novan and secured USD 12 million in non-dilutive capital from Ligand Pharmaceuticals immediately. This transaction further enables the accelerated advancement of the molluscum Phase III program of Novan.

 

Under the terms of this agreement, Ligand Pharmaceuticals will receive up to USD 20 million of milestone payments upon the achievement of certain regulatory milestones for SB206 by Novan. Along with this, Ligand Pharmaceuticals is entitled to receive royalties from Novan up to 7.0–10.0% based on aggregate annual net sales of SB206 or any other Novan molluscum product in North America. Novan will continue to have responsibility for all clinical development and regulatory execution of SB206 and the totality of the molluscum program activity. This deal permits Ligand Pharmaceuticals to contribute to the potential future revenue of a promising Phase III stage asset.

Reimbursement Scenario in Molluscum Contagiosum

Proactively approaching reimbursement can induce a positive impact both during the early stages of product development and well after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Molluscum Contagiosum (MC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Molluscum Contagiosum market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We performed a competitive market Intelligence analysis of the Molluscum Contagiosum market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers a descriptive overview of Molluscum Contagiosum (MC), explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Molluscum Contagiosum (MC) epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Molluscum Contagiosum (MC) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Molluscum Contagiosum market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Molluscum Contagiosum market.

Report Highlights

  • In the coming years, the Molluscum Contagiosum market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators, for innovative first-in-class curative drugs, and are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Molluscum Contagiosum (MC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Molluscum Contagiosum (MC). The launch of emerging therapies will significantly impact the Molluscum Contagiosum market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Molluscum Contagiosum Market Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Molluscum Contagiosum Pipeline Analysis
  • Molluscum Contagiosum Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Molluscum Contagiosum Market Report Key Strengths

  • 11-Year Forecast
  • 7MM Coverage
  • Molluscum Contagiosum (MC) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Molluscum Contagiosum Market Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the Molluscum Contagiosum Market share (%) distribution in 2019, and how would it look in 2032?
  • What would be the Molluscum Contagiosum total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings of the market across 7MM, and which country will have the largest Molluscum Contagiosum market Size during the forecast period (2019–2032)?
  • At what CAGR, the Molluscum Contagiosum market is expected to grow in 7MM during the forecast period (2019–2032)?
  • What would be the Molluscum Contagiosum market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the Molluscum Contagiosum market growth till 2032, and what will be the resultant market Size in the year 2032?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Molluscum Contagiosum?
  • What is the historical Molluscum Contagiosum patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Molluscum Contagiosum in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Out of all 7MM countries, which country would have the largest prevalent population of Molluscum Contagiosum during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow in 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Molluscum Contagiosum along with the approved therapy?
  • What are the current treatment guidelines for treating Molluscum Contagiosum in the US, Europe, and Japan?
  • What is the Molluscum Contagiosum marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Molluscum Contagiosum?
  • How many therapies are developed by each company for the treatment of Molluscum Contagiosum?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Molluscum Contagiosum?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Molluscum Contagiosum therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Molluscum Contagiosum and their status?
  • What key designations have been granted for the emerging therapies for Molluscum Contagiosum?
  • What are the global historical and forecasted markets for Molluscum Contagiosum?

Reasons to buy

  • The report will help develop business strategies by understanding trends shaping and driving the Molluscum Contagiosum market.
  • To understand the future market competition in the Molluscum Contagiosum market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Molluscum Contagiosum in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Molluscum Contagiosum market.
  • To understand the future market competition in the Molluscum Contagiosum market.

1. Key Insights

2. Report Introduction

3. Molluscum Contagiosum Market Overview at a Glance

3.1. Market Share (%) Distribution of Molluscum Contagiosum (MC) in 2019

3.2. Market Share (%) Distribution of Molluscum Contagiosum (MC) in 2032

4. Executive Summary of Molluscum Contagiosum (MC)

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Manifestations

5.3. Causes

5.4. Etiology

5.5. Pathogenesis

5.6. Diagnosis

5.7. Differential Diagnosis

5.8. Treatment and Management

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Population of Molluscum Contagiosum (MC)

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Total Prevalent Cases of Molluscum Contagiosum (MC) in the United States

6.4.2. Gender-Specific Cases of Molluscum Contagiosum (MC) in the United States

6.5. EU-5

6.5.1. Total Prevalent Cases of Molluscum Contagiosum (MC) in EU-5

6.5.2. Gender-Specific Cases of Molluscum Contagiosum (MC) in EU-5

6.6. Japan

6.6.1. Total Prevalent Cases of Molluscum Contagiosum (MC) in Japan

6.6.2. Gender-Specific Cases of Molluscum Contagiosum (MC) in Japan

7. Patient Journey

8. Emerging Therapies

8.1. Key Cross Competition

8.2. VP-102/Cantharidin: Verrica Pharmaceuticals

8.2.1. Drug Description

8.2.2. Regulatory Milestones

8.2.3. Other Development Activities

8.2.4. Clinical Development

8.2.5. Clinical Trials Information

8.2.6. Safety and Efficacy

8.2.7. Product Profile

8.3. SB206: Novan and Ligand Pharmaceuticals

8.3.1. Drug Description

8.3.2. Other Development Activities

8.3.3. Clinical Development

8.3.4. Clinical Trials Information

8.3.5. Safety and Efficacy

8.3.6. Product Profile

9. Other Promising Assets

9.1. Key Cross Competition

9.2. VB4-245: Veloce Biopharma

9.2.1. Drug Description

9.2.2. Other Development Activities

9.2.3. Clinical Development

9.2.4. Clinical Trials Information

9.2.5. Safety and Efficacy

9.2.6. Product Profile

10. Molluscum Contagiosum (MC): 7 Major Market Analysis

10.1. Key Findings

10.2. Market Size of Molluscum Contagiosum (MC) in 7MM

10.3. United States Market Size

10.3.1. Total Market Size of Molluscum Contagiosum in the United States

10.3.2. The US Market Size of Molluscum Contagiosum (MC) by Therapies

10.4. EU-5 Market

10.4.1. Total Market Size of Molluscum Contagiosum (MC) in EU-5

10.4.2. Germany

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. United Kingdom

10.5. Japan

10.5.1. Total Market Size of Molluscum Contagiosum (MC) in Japan

10.5.2. Market Size of Molluscum Contagiosum (MC) by Therapies in Japan

11. SWOT Analysis

12. Unmet Needs

13. KOL Views

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Table

Table 1: Summary of Molluscum Contagiosum (MC), Market, Epidemiology, and Key Events (2019–2032)

Table 2: Defense mechanisms used by Molluscum contagiosum virus to avoid immunologic reactions

Table 3: Total Prevalent Population of Molluscum Contagiosum (MC) in the 7MM (2019–2032)

Table 4: Total Prevalent Cases of Molluscum Contagiosum (MC) in the United States (2019–2032)

Table 5: Gender-Specific Cases of Molluscum Contagiosum (MC) in the United States (2019–2032)

Table 6: Total Prevalent Cases of Molluscum Contagiosum (MC) in EU5 (2019–2032)

Table 7: Gender-Specific Cases of Molluscum Contagiosum (MC) in EU-5 (2019–2032)

Table 8: Total Prevalent Cases of Molluscum Contagiosum (MC) in Japan (2019–2032)

Table 9: Gender-Specific Cases of Molluscum Contagiosum (MC) in Japan (2019–2032)

Table 10: VP-102, Clinical Trial Description, 2022

Table 11: SB-206, Clinical Trial Description, 2022

Table 12: SB-206, Clinical Trial Description, 2022

Table 13: 7MM Market Size of Molluscum Contagiosum (MC) in USD Million (2019–2032)

Table 14: The US Market Size of Molluscum Contagiosum (MC) in USD Million (2019–2032)

Table 15: The US Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Table 16: EU-5 Market Size of Molluscum Contagiosum (MC) in USD Million (2019–2032)

Table 17: Germany Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Table 18: France Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Table 19: Italy Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Table 20: Spain Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Table 21: United Kingdom Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Table 22: Japan Market Size of Molluscum Contagiosum (MC) in USD Million (2019–2032)

Table 23: Japan Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

List of Figures

Figure 1: Signs and symptoms of Molluscum contagiosum include bumps on the skin

Figure 2: Causes of Molluscum contagiosum

Figure 3: Total Prevalent Population of Molluscum Contagiosum (MC) in the 7MM (2019–2032)

Figure 4: Total Prevalent Cases of Molluscum Contagiosum (MC) in the US (2019–2032)

Figure 5: Gender-Specific Cases of Molluscum Contagiosum (MC) in the United States (2019-2032)

Figure 6: Total Prevalent Cases of Molluscum Contagiosum (MC) in EU5 (2019–2032)

Figure 7: Gender-Specific Cases of Molluscum Contagiosum (MC) in EU-5 (2019–2032)

Figure 8: Total Prevalent Cases of Molluscum Contagiosum (MC) in Japan (2019–2032)

Figure 9: Gender-Specific Cases of Molluscum Contagiosum (MC) in Japan (2019–2032)

Figure 10: 7MM Size of Molluscum Contagiosum (MC) in USD Million (2019–2032)

Figure 11: The US Market Size of Molluscum Contagiosum (MC) in USD Million (2019–2032)

Figure 12: The US Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Figure 13: EU-5 Market Size of Molluscum Contagiosum (MC), in USD Million (2019–2032)

Figure 14: Germany Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Figure 15: France Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Figure 16: Italy Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Figure 17: Spain Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Figure 18: The United Kingdom Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Figure 19: Japan Market Size of Molluscum Contagiosum (MC), in USD Million (2019–2032)

Figure 20: Japan Market Size of Molluscum Contagiosum (MC) by Therapies in USD Million (2019–2032)

Verrica Pharmaceuticals
Novan and Ligand Pharmaceuticals
Veloce Biopharma

 

Forward to Friend

Need A Quote